MENU
QNRX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

QNRX stock forecast, quote, news & analysis

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
QNRX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for QNRX with price predictions
Oct 30, 2026

QNRX's Stochastic Oscillator reaching overbought zone

The Stochastic Oscillator for QNRX moved into overbought territory on October 30, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

QNRX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QNRX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

QNRX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for QNRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QNRX's RSI Indicator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on QNRX as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for QNRX just turned positive on October 23, 2026. Looking at past instances where QNRX's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.

Following a +3.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNRX advanced for three days, in 176 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. QNRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.334) is normal, around the industry mean (3.162). P/E Ratio (-0.806) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 58 to 141.65B. VRTX holds the highest valuation in this group at 141.65B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was -15%. CRIS experienced the highest price growth at 55%, while ABOS experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 45
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
QNRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of biological products for cellular therapies

Industry Biotechnology

Industry
Biotechnology
Address
42127 Pleasant Forest Court
Phone
+1 703 980-4182
Employees
6
Web
https://www.quoinpharma.com
QNRX's Stochastic Oscillator reaching overbought zone